Authors
Loading...
Evaluates Ganodermadiol's antidiabetic potential using biological inhibitors from Ganoderma lucidum, suggesting a promising therapeutic approach.
Afzal et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: